¡¡¡¡Õª Òª£º¡¡Ä¿µÄ ̽ÌÖÆß·úÍéÎüÈëÂé×í¶ÔÀÏÄêÊÖÊõ»¼ÕßËÕÐѼ°ÈÏÖª¹¦ÄܵÄÓ°Ïì¡£·½·¨ Ñ¡Ôñ2016Äê8Ô—2018Äê8ÔÂÎÒÔºÊÕÖεÄ80ÀýÀÏÄêÊÖÊõ»¼Õß×÷ΪÑо¿¶ÔÏó, ²ÉÓÃËæ»úÊý×Ö±í·¨·ÖΪ2×é¸÷40Àý¡£¶ÔÕÕ×éÓ¦Óñû²´·Ó, ¹Û²ì×éÎüÈëÆß·úÍé, ±È½Ï2×黼ÕßÕöÑÛʱ¼ä¡¢°Î¹Üʱ¼ä¡¢ÌÛÍ´ÊÓ¾õÄ£ÄâÆÀ·Ö·¨ (VAS) ÆÀ·Ö¼°ÈÏÖª¹¦ÄÜ¡£½á¹û ¹Û²ì×éÕöÑÛ¡¢°Î¹Üʱ¼ä¼°VASÆÀ·Ö¾ùÉÙÓÚ¶ÔÕÕ×é, ²îÒì¾ßÓÐͳ¼ÆѧÒâÒå (P<0.05) ;¹Û²ì×éÊõºóÈÏÖª¹¦ÄÜÆÀ·Ö¸ßÓÚ¶ÔÕÕ×é, ²îÒì¾ßÓÐͳ¼ÆѧÒâÒå (P<0.05) ¡£½áÂÛ ÀÏÄêÊÖÊõ»¼ÕßʹÓÃÆß·úÍéÎüÈëÂé×íÄܹ»Ã÷ÏÔËõ¶ÌÊõºóËÕÐÑʱ¼ä, ½µµÍÊõºóÌÛÍ´, ´Ù½øÊõºóÈÏÖª¹¦Äָܻ´¡£
¡¡¡¡¹Ø¼ü´Ê£º¡¡ÀÏÄêÊÖÊõ; Æß·úÍé; ÎüÈëÂé×í; ËÕÐÑ; ÈÏÖª¹¦ÄÜ; Ó°Ïì;
¡¡¡¡Abstract£º¡¡Objective To explore the effect of seven flurane inhalation anesthesia on recovery and cognitive function in elderly patients undergoing operation.Methods 80 elderly surgical patients admitted to our hospital from Aμgust 2016 to Aμgust 2018 were selected as the study subjects.They were divided into two groups by random number table method, 40 cases in each group.The control group was treated with propofol, and the observation group inhaled seven halothane.Eye opening time, extubation time, visual analogue scale (VAS) score and cognitive function were compared between the two groups.Results The time of opening eyes, extubation and VAS score in the observation group were less than those in the control group, with statistical significance (P<0.05) ;the cognitive function score in the observation group was higher than that in the control group, with statistical significance (P<0.05) .Conclusion Sevoflurane inhalation anesthesia can significantly shorten the recovery time, reduce postoperative pain and restore cognitive function in elderly patients undergoing surgery.
¡¡¡¡Keyword£º¡¡Geriatric surgery; Seven halothane; Inhalation anesthesia; Revive; Cognitive function; Influence;
¡¡¡¡Ëæ×ÅÄêÁäµÄÔö³¤, ÀÏÄêÈ˸÷Æ÷¹Ù¹¦ÄÜÖð½¥ÍË»¯, ʵʩÊÖÊõÖÎÁÆʱ¶ÔÂé×í¼°ÊÖÊõµÄÄÍÊÜÁ¦¼õÈõ, ÏàÓ¦µÄ·çÏÕÒ²ËæÖ®Ôö´ó, Òò´Ë, ¶ÔÊÖÊõ¼°Âé×íµÄÒªÇó½Ï¸ß¡£ÎüÈëÐÔÂé×íÊǽ«Âé×íÒ©Îïͨ¹ýÃæÕÖÎüÈ뾺ôÎüµÀ¶ø½øÈ뻼ÕßÌåÄÚ, ´Ó¶ø·¢»ÓÂé×íЧ¹û, Æä¾ßÓÐÂé×í¹¦ÄÜÇ¿¡¢¿É¿ØÐԸߵÈÌص㡣Æß·úÍéÊÇÁÙ´²½Ï³£Ê¹ÓõÄÎüÈëÐÔÂé×íÒ©, Æä¶ÔÆøµÀ´Ì¼¤·´Ó¦Çá΢¡¢Âé×íÓÕµ¼¿ì, ÊõºóËÕÐÑ¿ì, ÇÒ¶Ô¸ÎÔàµÄ¶¾ÐÔË𺦽ÏС[1]¡£±¾Ñо¿½øÒ»²½Ì½ÌÖÆß·úÍéÎüÈëÂé×í¶ÔÀÏÄêÊÖÊõ»¼ÕßËÕÐÑʱ¼ä¼°ÈÏÖª¹¦ÄܵÄÓ°Ïì, ÏÖ±¨¸æÈçÏ¡£
¡¡¡¡1¡¢ ×ÊÁÏÓë·½·¨
¡¡¡¡1.1¡¢ Ò»°ã×ÊÁÏ
¡¡¡¡Ñ¡Ôñ2016Äê8Ô—2018Äê8ÔÂÎÒÔºÊÕÖεÄ80ÀýÀÏÄêÊÖÊõ»¼Õß×÷ΪÑо¿¶ÔÏó, ²ÉÓÃËæ»úÊý×Ö±í·¨·ÖΪ2×é, ¸÷40Àý¡£¶ÔÕÕ×éÄÐ23Àý, Å®17Àý;ÄêÁä60Ëê¡«75Ëê, ƽ¾ùÄêÁä (67.50±4.42) Ëê;ÌåÖØ48¡«87 kg, ƽ¾ù (66.27±5.45) kg;ÃÀ¹úÂé×íҽʦлá (ASA) ·Ö¼¶:¢ñ¼¶27Àý¡¢¢ò¼¶13Àý;ƽ¾ùÊÖÊõʱ¼ä (2.41±0.62) h¡£¹Û²ì×éÄÐ24Àý, Å®16Àý;ÄêÁä62Ëê¡«78Ëê, ƽ¾ùÄêÁä (68.15±5.03) Ëê;ÌåÖØ50¡«85 kg, ƽ¾ù (65.58±5.07) kg;ASA·Ö¼¶:¢ñ¼¶30Àý¡¢¢ò¼¶10Àý;ƽ¾ùÊÖÊõʱ¼ä (2.63±0.57) h¡£2×黼ÕßÐÔ±ð¡¢ÄêÁä¡¢ÌåÖØ¡¢ASA·Ö¼¶¼°ÊÖÊõʱ¼äµÈÒ»°ã×ÊÁϲîÒìÎÞͳ¼ÆѧÒâÒå (P>0.05) , ¾ßÓпɱÈÐÔ¡£±¾Ñо¿¾Ò½ÔºÂ×ÀíίԱ»áÅú×¼, ÇÒ»¼Õß»ò¼ÒÊô¾ù×ÔԸǩÊðÖªÇéͬÒâÊé¡£
¡¡¡¡1.2¡¢ ·½·¨
¡¡¡¡»¼Õß½øÈëÊÖÊõÊÒºó, ½¨Á¢¾²Âöͨ·, ÓèÐĵç¼à»¤, ÃÜÇй۲ìÐÄÂÊ¡¢ÑªÑ¹¡¢Âö²«¡¢ºôÎü¡¢¾²ÂöѪÑõ±¥ºÍ¶ÈµÈ±ä»¯, ÓèÃæÕÖÑõÆøÎüÈë¡£2×黼Õß¾ùʹÓñû²´·Ó (Corden Pharma S.P.A, ½ø¿ÚÒ©Æ·×¢²áÖ¤ºÅH20100646) 1.5¡«2.5mg/kg¡¢èÛéÚËáÊæ·ÒÌ«Äá×¢ÉäÒº (Ò˲ýÈ˸£Ò©ÒµÓÐÏÞÔðÈι«Ë¾, ¹úÒ©×¼×ÖH20054171) 0.5μg/kg½øÐÐÂé×íÓÕµ¼, ¶ÔÕÕ×éÓ¦Óñû²´·Ó×¢ÉäÒº4¡«12 mg/ (kg·h) , Êæ·ÒÌ«Äá¼ä¶Ï×¢Éä½øÐÐÂé×íά³Ö¡£¹Û²ì×éÂé×íÓÕµ¼ºó¾Âé×íÃæÕÖÎüÈëÆß·úÍé (½ËÕºãÈðÒ½Ò©¹É·ÝÓÐÏÞ¹«Ë¾, ¹úÒ©×¼×ÖH20040772) 1¡«2 MAC, ¼ä¶Ï×¢ÉäÊæ·ÒÌ«Äá½øÐÐÂé×íά³Ö¡£
¡¡¡¡1.3¡¢ ¹Û²ìÖ¸±ê
¡¡¡¡Êõºó¼Ç¼2×黼ÕßÕöÑÛʱ¼ä¡¢°Î¹Üʱ¼ä¼°ÌÛÍ´³Ì¶È¡£²ÉÓÃÊÓ¾õÄ£ÄâÆÀ·Ö·¨ (VAS) ÆÀ¹À2×黼Õ߰ιܺóÌÛÍ´³Ì¶È, ³¤¶ÈΪ10 cmµÄ±ê³ß, ±êʾ¿Ì¶È0 cm¡«10 cm, ¼ÇΪ0¡«10·Ö, ÆäÖÐ0·Ö±íʾÎÞÍ´;1¡«3·ÖΪÇá¶ÈÌÛÍ´;4¡«6·ÖΪÖжÈÌÛÍ´;7¡«10·ÖΪÖضÈÌÛÍ´¡£·Ö±ðÓÚÊõÇ°, Êõºó1d¡¢2d¡¢3d, ²ÉÓüòÒ×ÖÇÁ¦×´Ì¬¼ì²éÁ¿±í (MMSE) [2]ÆÀ¹À2×黼ÕßµÄÈÏÖª¹¦ÄÜ, Ö÷Òª°üÀ¨Ê±¼ä¶¨ÏòÁ¦¡¢µØµã¶¨ÏòÁ¦¡¢ÓïÑÔ¡¢¼´¿Ì¼ÇÒäÁ¦¼°¼ÆËãÁ¦µÈ30Ïî, ÿÏî»Ø´ðÕýȷΪ1·Ö, »Ø´ð´íÎó»ò»Ø´ð²»ÖªµÀΪ0·Ö, ×Ü·ÖΪ30·Ö, µÃ·ÖÓëÈÏÖªÄÜÁ¦³ÉÕý±È¡£
¡¡¡¡1.4¡¢ ͳ¼Æѧ·½·¨
¡¡¡¡²ÉÓÃSPSS18.0ͳ¼ÆѧÈí¼þ½øÐÐÊý¾Ý´¦Àí, ¼ÆÁ¿×ÊÁÏÒÔ±íʾ, ²ÉÓÃt¼ìÑé, P<0.05Ϊ²îÒì¾ßÓÐͳ¼ÆѧÒâÒå¡£
¡¡¡¡2¡¢ ½á¹û
¡¡¡¡2.1¡¢ ÁÙ´²Ö¸±ê
¡¡¡¡¹Û²ì×éÕöÑÛ¡¢°Î¹Üʱ¼ä¼°VASÆÀ·Ö¾ùÉÙÓÚ¶ÔÕÕ×é, ²îÒì¾ßÓÐͳ¼ÆѧÒâÒå (P<0.05) ¡£¼û±í1¡£
¡¡¡¡±í1 2 ×éÕöÑ۰ιÜʱ¼ä¼°VASÆÀ·Ö±È½Ï
¡¡¡¡2.2¡¢ ÈÏÖª¹¦ÄÜ
¡¡¡¡¹Û²ì×éÊõºóÈÏÖª¹¦ÄÜÆÀ·Ö¸ßÓÚ¶ÔÕÕ×é, ²îÒì¾ßÓÐͳ¼ÆѧÒâÒå (P<0.05) ¡£¼û±í2¡£
¡¡¡¡±í2 2 ×éÈÏÖª¹¦ÄܱȽÏ
¡¡¡¡3¡¢ ÌÖÂÛ
¡¡¡¡ÀÏÄ껼Õ߸÷Æ÷¹ÙË¥ÍË¡¢ÊÖÊõÄÍÐÔ²î, ÇҺϲ¢¶àÖÖ»ù´¡¼²²¡, µ¼ÖÂÊÖÊõºó»Ö¸´Âý, ÊõºóÒ׳öÏÖ²»Äܼ¯ÖÐ×¢ÒâÁ¦¡¢¼ÇÒäÁ¦¼°Àí½âÄÜÁ¦Ï½µµÈÈÏÖª¹¦ÄÜË𺦱íÏÖ, ËùÒÔÂé×í·½Ê½µÄÑ¡ÔñÖÁ¹ØÖØÒª[3]¡£±¾´ÎÑо¿¶Ô±È·ÖÎöÁ˱û²´·Ó¾²Âö×¢ÉäÓëÎüÈëÆß·úÍé¶ÔÀÏÄêÊÖÊõ»¼ÕßËÕÐѼ°ÈÏÖª¹¦ÄܵÄÓ°Ïì, ½á¹ûÏÔʾ²ÉÓÃÆß·úÍéµÄ¹Û²ì×éÕöÑÛ¡¢°Î¹Üʱ¼ä¼°VASÆÀ·Ö¾ùµÍÓÚ¶Ô²ÉÓñû²´·ÓµÄ¶ÔÕÕ×é, ÇÒ¹Û²ì×éÈÏÖª¹¦ÄÜÆÀ·Ö¸ßÓÚ¶ÔÕÕ×é (P<0.05) ¡£
¡¡¡¡±û²´·ÓÊÇÒ»ÖÖÍé»ùËáÀàµÄ¶ÌЧ¾²ÂöÂé×íÒ©, ¾ßÓÐÖ¬ÈÜÐÔÇ¿, ÆðЧ¿ì, ÎÞÃ÷ÏÔÒ©ÎïÐî»ýµÄÌصã, ΪĿǰÁÙ´²³£ÓõÄÈ«ÉíÂé×íÓÕµ¼ºÍά³ÖÒ©Îï¡£±û²´·Ó¿Éͨ¹ý½µµÍ½»¸ÐËõѪ¹ÜÉñ¾»îÐÔÀ©ÕÅÍâÖÜѪ¹Ü, ÒÔ¼°ÒÖÖÆÃÔ×ßÉñ¾½éµ¼µÄ¾±²¿Ñ¹Á¦¸ÐÊÜÆ÷¶ÔÂé×íºóµÄѪÁ÷¶¯Á¦Ñ§²úÉúÒ»¶¨Ó°Ïì;½øÈëѪÄÔÆÁÕϺó¿ÉÑ¡ÔñÐԵؼõµÍ¾Ö²¿ÄÔѪÁ÷Á¿, ͨ¹ýÔöÇ¿γ°±»ù¶¡Ëá (GABA) µÄÉñ¾ÒÖÖÆ×÷ÓÃÒÔ¼°½µµÍÐË·ÜÐÔÉñ¾Ôª»îÐÔ, ¶ÔÊõºóÈÏÖª¹¦ÄܲúÉúÓ°Ïì[4], ʹµÃÆäÔÚÀÏÄ껼ÕßÖеÄÓ¦ÓÃЧ¹û²»ÊǺÜÀíÏë¡£ÎüÈëÐÔÂé×íҩͨ¹ý·ÎÅݶ¯Âö½øÈëѪҺ, Ëæ×ÅѪҺѻ·Í¸¹ýѪÄÔÄÔÆÁÕϵ½´ïÄÔ²¿, ½øÈëÖÐÊàÉñ¾ÏµÍ³, ´Ó¶ø×è¶ÏÉñ¾´«µ¼¹¦ÄÜ, Æðµ½Âé×íЧ¹û, Æ伫ÉÙ±»¸ÎÔà´úл»òÉöÔàÅÅй, Ö÷ÒªÒÔÔÐξºôÎüµÀÅųöÌåÍâ¡£Æß·úÍéÊôÓÚÎüÈëÐÔÂé×íÒ©Îï, Âé×íÓÕµ¼ºÍ¾õÐÑƽÎȶøѸËÙ, Âé×íÉî¶ÈÈÝÒ×µ÷½Ú, Âé×íÉî¶ÈÓëºôÎüÒÖÖÆ»ù±¾Æ½ÐÐ, Âé×íºóµÄºôÎüÒÖÖƱȷúÍéÇá[5]¡£Ëæ×ÅÂé×íÓÕµ¼, »úÌåºôÎüƵÂÊÖð½¥Ôö¿ì, ³±ÆøÁ¿Ôö¼Ó, µ«·ÖÖÓͨÆøÁ¿»ù±¾²»±ä, ¿Éͨ¹ý¸¨ÖúºôÎü±£³ÖºÏÊÊͨÆøÁ¿;Æß·úÍéÎüÈëÂé×íºó, »¼ÕßÐÄÂÉ»ù±¾±£³Ö²»±ä»òÂÔϽµ, ¼«ÉÙ³öÏÖÐÄÂÉʧ³£, Òò´Ë, Ó¦ÓÃÓÚÀÏÄ껼ÕßÂé×íʱ, ¶ÔºôÎüϵͳ¼°Ñ»·ÏµÍ³µÄ¸ÉÈŽÏС¡£ÔÚÍ£Ö¹Æß·úÍéÎüÈëºó»úÌå·ÎÅÝÄÚŨ¶È»áѸËÙ½µµÍ, ÌåÄÚ²ÐÓàÒ©ÎᄎôÎü¿ÉѸËÙÅųö;Æß·úÍéµÄÖ¬ÈÜÐÔС, ¾ßÓеÍÈܽâ¶ÈµÄÌصã, ¶ÔÀÏÄêÊÖÊõ»¼Õß¾ßÓпìËÙËÕÐѵÄЧ¹û, ²»»áÓ°Ï컼ÕßËÕÐÑʱ¼ä, Äܹ»Î¬³Ö»¼ÕßÌåÑ»·Îȶ¨[6]¡£Í¬Ê±Ñо¿±íÃ÷, Æß·úÍé¿Éͨ¹ý¼¤»îÈýÁ×ËáÏÙÜÕ (ATP) Ãô¸ÐÐÔ¼ØͨµÀ, ÒÖÖÆÒ»Ñõ»¯µªºÏø»îÐÔ, ½µµÍ¹È°±ËáÊÍ·Å, ¼õÉÙϸ°ûÄڸƳ¬ÔØ, ¼¤»îºËÒò×ÓκB;¾¶¼°¿¹Ñõ»¯µ÷¿Øϸ°ûµòÍöµÈ¶à¸ö;¾¶, ²úÉúÄÔ±£»¤×÷ÓÃ, ÓÐÀûÓÚ±ÜÃâºÍ¼õÇáÀÏÄêÈ«ÂéÊÖÊõ»¼ÕßµÄÈÏÖª¹¦ÄÜËðÉË[7]¡£
¡¡¡¡×ÛÉÏËùÊö, ÀÏÄêÊÖÊõ»¼ÕßʹÓÃÆß·úÍéÎüÈëÂé×íÄܹ»Ã÷ÏÔËõ¶ÌÊõºóËÕÐÑʱ¼ä, ½µµÍÊõºóÌÛÍ´, »Ö¸´»¼ÕßÈÏÖª¹¦ÄÜ¡£
¡¡¡¡²Î¿¼ÎÄÏ×
¡¡¡¡[1]Õç×Æ, Íõ»Ô.ÀÏÄêÈËÆß·úÍéÎüÈëÂé×íÓë±û²´·ÓÈ«¾²ÂöÂé×íµÄÓÅȱµã[J].ҽѧ×ÛÊö, 2018, 24 (11) :2259-2260.
¡¡¡¡[2]Çà°¬Áæ.±û²´·Ó¾²ÂöÂé×í¶ÔÀÏÄêÁ¼ÐÔÇ°ÁÐÏÙÔöÉú»¼ÕßÊõºó¼òÒ×ÖÇÁ¦×´Ì¬¼ì²éÁ¿±íÆÀ·Ö¼°ÑªÇåÉñ¾ÔªÌØÒìÐÔÏ©´¼»¯Ã¸ºÍÉñ¾Éú³¤Òò×Óˮƽ±ä»¯µÄÓ°Ïì[J].ÖйúÒ½Ò©, 2018, 13 (1) :125-128.
¡¡¡¡[3]ÁõÖ¾Á«.ӲĤÍâÂé×íÓëÈ«ÉíÂé×í¶ÔÀÏÄ껼ÕßÊõºóÈÏÖª¹¦ÄܵÄÓ°Ïì[J].¼ìÑéҽѧÓëÁÙ´², 2013, 10 (14) :1790-1791¡¢1793.
¡¡¡¡[4]»Æ½¡³Ð, ÁõÏþç, ÂÞÏ£, µÈ.±û²´·ÓÂé×íÊõºóÒâʶºÍÈÏÖª¹¦Äָܻ´µÄ¹Û²ì[J].¹ãÖÝҽѧԺѧ±¨, 2006, 34 (6) :70-73.
¡¡¡¡[5]ÕÅ»á¾ê.Æß·úÍéÎüÈëÂé×íÓÃÓÚÀÏÄ껼ÕßÈ«ÉíÂé×íÊÖÊõÖеÄÁÆЧ¹Û²ì[J].ÁÙ´²Ò½Ò©ÎÄÏ×ÔÓÖ¾, 2015, 2 (27) :5582-5583.
¡¡¡¡[6]ÍõÒàÑþ, Àîع, º«Ñ§²ý, µÈ.Æß·úÍé¶ÔÀÏÄê¹Ú×´¶¯ÂöÖàÑùÓ²»¯ÐÔÐÄÔಡ»¼ÕßΧÊõÆÚѪÁ÷¶¯Á¦Ñ§µ÷¿ØºÍÐļ¡µÄÓ°ÏìÑо¿[J].ÖйúÏÖ´úҽѧÔÓÖ¾, 2018, 28 (7) :88-93.
¡¡¡¡[7]ËïÃô, Òó»ý»Û, Áºéª, µÈ.Æß·úÍé¶ÔÊõºóÈÏÖªÕÏ°Ó°ÏìµÄÑо¿½øÕ¹[J].Çൺ´óѧҽѧԺѧ±¨, 2016, 52 (1) :119-121¡¢124.